BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Sysco calls on Teamsters to end LA strike after economic deal reached
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $81 at Oppenheimer
February 22, 2019 7:47 AM ESTOppenheimer analyst Leland Gershell lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $81.00 (from $92.00) while maintaining a Perform rating following the company's 4Q. BMRN reported revenue of $353M, within the mid-range of guidance, but below consensus of $377M, resulting from modest... More



